Equity Profile

RCUS

Arcus Biosciences, Inc.

Health CareBiotechnology$2.8B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Arcus Biosciences, Inc. is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health. Investors will look for improvement or deterioration compared to previous quarters.

N/A

Revenue Growth

Although revenue estimates are not available, any reported revenue will be closely scrutinized as it reflects the company's market performance and product acceptance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

RCUS Q2-2026 Earnings Preview

Context

Company Snapshot

Arcus Biosciences, Inc. is a biotechnology company focused on developing innovative cancer therapies. With a market cap of $3 billion, it operates in the health care sector, which is increasingly important as the demand for advanced medical treatments grows.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+15.06%

Avg Stock Reaction

-0.13%

Last Quarter Recap

In Q1-2026, Arcus reported an EPS of -$1.02, missing expectations by about 11%. The stock saw a slight increase of 0.04% the following day, indicating a mixed market reaction.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has a history of beating EPS estimates but lacks revenue guidance. Investors are cautious given the recent performance.

Bull Case

If Arcus can show significant improvements in EPS and any positive revenue, it could signal a turnaround, leading to increased investor confidence.

Bear Case

Conversely, if the company continues to report losses without a clear path to profitability, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

The EPS figure will be critical in assessing whether the company is moving towards profitability or continuing to struggle.

Is there any revenue guidance or updates on product development?

Any insights into revenue or product pipeline can significantly influence investor sentiment and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be overly cautious about Arcus's ability to improve EPS based on recent trends, failing to account for potential breakthroughs in their product pipeline.

Supporting Evidence

The company has a history of beating EPS estimates 75% of the time, indicating potential for positive surprises.

Options pricing suggests a significant move, which could indicate that traders are expecting a larger shift in sentiment.

Key Risk

If the EPS comes in better than -$0.80, it could shift the narrative towards a more optimistic outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Arcus can turn its financial performance around after a series of mixed results.

Bull Confirmed If

An EPS improvement to -$0.80 or better would confirm the bull case.

Bear Confirmed If

An EPS worse than -$1.10 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±33.5%

Historical Avg

±2.9%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±33.5% while RCUS has averaged ±2.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

56.4%

Calls (400)P/C Ratio: 0.40Puts (100)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arcus beats expectations, history suggests the stock could rise by about 1.35%, confirming a positive outlook.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may remain flat or see a slight decline.

Miss

Should the company miss expectations, history indicates a potential drop of around 4.57%, reflecting ongoing investor concerns.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the product pipeline and expected timelines for new therapies.
2Management's commentary on cost management and pathways to profitability.
3Insights into market demand for their therapies and competitive positioning.
4Any news on partnerships or collaborations that could enhance growth prospects.
5Details on research and development expenditures and their expected impact.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Arcus Biosciences, Inc. is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health. Investors will look for improvement or deterioration compared to previous quarters.

N/A

Revenue Growth

Although revenue estimates are not available, any reported revenue will be closely scrutinized as it reflects the company's market performance and product acceptance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

RCUS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+15.06%

Avg Stock Reaction

-0.13%

Last Quarter Recap

In Q1-2026, Arcus reported an EPS of -$1.02, missing expectations by about 11%. The stock saw a slight increase of 0.04% the following day, indicating a mixed market reaction.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has a history of beating EPS estimates but lacks revenue guidance. Investors are cautious given the recent performance.

Bull Case

If Arcus can show significant improvements in EPS and any positive revenue, it could signal a turnaround, leading to increased investor confidence.

Bear Case

Conversely, if the company continues to report losses without a clear path to profitability, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

The EPS figure will be critical in assessing whether the company is moving towards profitability or continuing to struggle.

Is there any revenue guidance or updates on product development?

Any insights into revenue or product pipeline can significantly influence investor sentiment and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be overly cautious about Arcus's ability to improve EPS based on recent trends, failing to account for potential breakthroughs in their product pipeline.

Supporting Evidence

The company has a history of beating EPS estimates 75% of the time, indicating potential for positive surprises.

Options pricing suggests a significant move, which could indicate that traders are expecting a larger shift in sentiment.

Key Risk

If the EPS comes in better than -$0.80, it could shift the narrative towards a more optimistic outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Arcus can turn its financial performance around after a series of mixed results.

Bull Confirmed If

An EPS improvement to -$0.80 or better would confirm the bull case.

Bear Confirmed If

An EPS worse than -$1.10 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±33.5%

Historical Avg

±2.9%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±33.5% while RCUS has averaged ±2.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

56.4%

Calls (400)P/C Ratio: 0.40Puts (100)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arcus beats expectations, history suggests the stock could rise by about 1.35%, confirming a positive outlook.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may remain flat or see a slight decline.

Miss

Should the company miss expectations, history indicates a potential drop of around 4.57%, reflecting ongoing investor concerns.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the product pipeline and expected timelines for new therapies.
2Management's commentary on cost management and pathways to profitability.
3Insights into market demand for their therapies and competitive positioning.
4Any news on partnerships or collaborations that could enhance growth prospects.
5Details on research and development expenditures and their expected impact.